PMID- 31490707
OWN - NLM
STAT- MEDLINE
DCOM- 20200413
LR  - 20200413
IS  - 1747-4132 (Electronic)
IS  - 1747-4124 (Linking)
VI  - 13
IP  - 10
DP  - 2019 Oct
TI  - Infections and malignancies risks related to TNF-alpha-blocking agents in pediatric 
      inflammatory bowel diseases.
PG  - 957-961
LID - 10.1080/17474124.2019.1663173 [doi]
AB  - Introduction: Tumor necrosis factor-alpha (TNF-alpha)-blocking agents are drugs approved 
      for the treatment of inflammatory bowel diseases (IBDs). Infliximab and 
      adalimumab are approved for the treatment of IBD in the pediatric setting with 
      the improvement of therapeutic management. Biological agents, also in the 
      pediatric population, can be administered either alone or in combination with 
      immunomodulators. Their use has raised safety concerns regarding the risk of 
      infections and malignancies.Areas covered: A broad review of the safety concerns 
      for the use of anti-TNF-alpha drugs in children with IBD was performed, and 
      information regarding the risk of infections and malignancies were updated, also 
      in comparison with the safety of traditional drugs such as steroids and/or 
      immunosuppressants.Expert commentary: Anti-TNF-alpha drugs have shown favorable 
      safety profiles, and adalimumab treatment is associated with lower immunogenicity 
      compared with infliximab. Heightened awareness and vigilant surveillance leading 
      to prompt diagnosis and treatment are important for optimal management.
FAU - Alvisi, Patrizia
AU  - Alvisi P
AD  - Pediatric Gastroenterology Unit, Maggiore Hospital, Bologna, Italy.
FAU - Dipasquale, Valeria
AU  - Dipasquale V
AD  - Pediatric Gastroenterology Unit, Department of Human Pathology in Adulthood and 
      Childhood "G. Barresi", University of Messina, Messina, Italy.
FAU - Barabino, Arrigo
AU  - Barabino A
AD  - Pediatric Gastroenterology Unit, Institute Giannina Gaslini, Genova, Italy.
FAU - Martellossi, Stefano
AU  - Martellossi S
AD  - Pediatric Department, Gastroenterology, Digestive Endoscopy and Nutrition Unit, 
      Institute for Maternal and Child Health I.R.C.C.S. Burlo Garofalo, Trieste, 
      Italy.
FAU - Miele, Erasmo
AU  - Miele E
AD  - Department of Translational Medical Science (Section of Pediatrics), and European 
      Laboratory for the Investigation of Food-Induced Diseases, University Federico 
      II, Naples, Italy.
FAU - Lionetti, Paolo
AU  - Lionetti P
AD  - Pediatric Gastroenterology and Nutrition Unit, University of Florence-Meyer 
      Hospital, Florence, Italy.
FAU - Lombardi, Giuliano
AU  - Lombardi G
AD  - Pediatric Gastroenterology and Endoscopy Unit, Spirito Santo Hospital, Pescara, 
      Italy.
FAU - Cucchiara, Salvatore
AU  - Cucchiara S
AD  - Department of Pediatrics and Infantile Neuropsychiatry, Pediatric 
      Gastroenterology and Liver Unit, Sapienza University of Rome, Rome, Italy.
FAU - Torre, Giuliano
AU  - Torre G
AD  - Hepatology, Gastroenterology and Nutrition Unit, Bambino Gesu Children's 
      Hospital, Rome, Italy.
FAU - Romano, Claudio
AU  - Romano C
AD  - Pediatric Gastroenterology Unit, Department of Human Pathology in Adulthood and 
      Childhood "G. Barresi", University of Messina, Messina, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190906
PL  - England
TA  - Expert Rev Gastroenterol Hepatol
JT  - Expert review of gastroenterology & hepatology
JID - 101278199
RN  - 0 (Tumor Necrosis Factor Inhibitors)
RN  - Pediatric Crohn's disease
RN  - Pediatric ulcerative colitis
SB  - IM
MH  - Age of Onset
MH  - Colitis, Ulcerative/*drug therapy/epidemiology/immunology
MH  - Crohn Disease/*drug therapy/epidemiology/immunology
MH  - Humans
MH  - *Immunocompromised Host
MH  - Neoplasms/*chemically induced/epidemiology/immunology
MH  - Opportunistic Infections/*chemically induced/epidemiology/immunology
MH  - Prognosis
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
MH  - Tumor Necrosis Factor Inhibitors/*adverse effects
OTO - NOTNLM
OT  - Inflammatory bowel disease
OT  - TNF-alpha
OT  - biological therapy
OT  - child
OT  - safety
EDAT- 2019/09/07 06:00
MHDA- 2020/04/14 06:00
CRDT- 2019/09/07 06:00
PHST- 2019/09/07 06:00 [pubmed]
PHST- 2020/04/14 06:00 [medline]
PHST- 2019/09/07 06:00 [entrez]
AID - 10.1080/17474124.2019.1663173 [doi]
PST - ppublish
SO  - Expert Rev Gastroenterol Hepatol. 2019 Oct;13(10):957-961. doi: 
      10.1080/17474124.2019.1663173. Epub 2019 Sep 6.